AMRN - Amarin Corporation plc
16.68 +0.11 (0.66%)
After hours: 5:51PM EST
| Previous Close | 16.68 |
| Open | 16.97 |
| Bid | 16.57 x 800 |
| Ask | 16.68 x 900 |
| Day's Range | 16.22 - 17.09 |
| 52 Week Range | 2.35 - 23.34 |
| Volume | 4,314,686 |
| Avg. Volume | 18,558,839 |
| Market Cap | 5.351B |
| Beta (3Y Monthly) | -0.13 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.37 |
| Earnings Date | May 4, 2017 - May 8, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 34.80 |
- Motley Fool•yesterday
Here's Why Amarin Fell 13.6% in November
New clinical data gave investors pause, while management wisely took advantage of the soaring stock price to raise capital through a share offering.
- ACCESSWIRE•5 days ago
Today's Research Reports on Trending Tickers: Amarin Corporation and Agios Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / December 7, 2018 / U.S. equities finished modestly lower on Thursday as trade concerns were reignited after the arrest of a Huawei senior executive. The Dow Jones Industrial ...
- Zacks•8 days ago
Amarin (AMRN) Stock Sinks As Market Gains: What You Should Know
Amarin (AMRN) closed at $17.67 in the latest trading session, marking a -1.83% move from the prior day.
- Motley Fool•8 days ago
2 Biotech Stocks Poised for Big Gains in 2019
Amarin and Novavax could crush the broader markets in 2019. Here's why.
- ACCESSWIRE•9 days ago
Today's Research Reports on Trending Tickers: Immunomedics and Amarin
A “trade war truce” was expected to come from the dinner between President Trump and Chinese President Xi Jinping over the weekend and that is what exactly happened. China and the United States agreed to a ceasefire in their bitter trade war on Saturday, including no escalated tariffs in Jan. Trump will leave tariffs on $200 billion worth of Chinese imports at 10 percent at the beginning of the new year. The Nasdaq Composite Index climbed 0.79 percent to close at 7,330.54.
- InvestorPlace•11 days ago
Serious Questions Surround CV Sciences Stock
CV Sciences, somewhat incredibly, has risen by a factor of 21x in just the last year. CVSI stock, in fact, has risen more than 1,000% just since April. Unlike a number of OTC marijuana-related stocks, CV Sciences has a real business.
- GlobeNewswire•14 days ago
Market Trends Toward New Normal in Amarin, BioSpecifics Technologies, Cavco Industries, Iconix Brand Group, A-Mark Precious Metals, and Core-Mark Holding — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Motley Fool•14 days ago
Why U.S. Steel, Amarin, and Papa John's International Slumped Today
Find out why these stocks missed out on an afternoon market rebound.
- Motley Fool•14 days ago
Why Amarin's Latest News Caused Shares to Crash 13% Today
The company's diluting existing shareholders to finance expenses ahead of an expected increase in demand.
- CNBC•15 days ago
Stocks making the biggest move premarket: UTX, AAPL, HIBB, NVS, TSLA & more
These are the stocks posting the largest moves before the bell.
- Benzinga•15 days ago
The Daily Biotech Pulse: Abeona Fires CEO, Loxo Passes FDA Muster, Bristol-Myers Flunks Lung Cancer Trial
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 26) Emergent Biosolutions Inc (NYSE: EBS ) Vericel Corp ...
- GlobeNewswire•15 days ago
Amarin Prices Public Offering of American Depositary Shares
Amarin Corporation plc (AMRN) today announced the pricing of the underwritten public offering of its American Depositary Shares ("ADSs") for gross proceeds of approximately $200.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Amarin. In addition, Amarin has granted the underwriters a 30-day option to purchase approximately $30.0 million of additional ADSs. Jefferies and Cantor Fitzgerald & Co. are acting as the joint book-running managers for the offering.
- GlobeNewswire•15 days ago
Amarin Announces Proposed Public Offering of American Depositary Shares
Amarin Corporation plc (AMRN) today announced a registered underwritten public offering of its American Depositary Shares (“ADSs”). All of the shares in the proposed offering are to be sold by Amarin. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Jefferies and Cantor Fitzgerald & Co. are acting as the joint book-running managers for the offering.
Market Realist•15 days agoA Look at Amarin Corporation’s Stock Performance Year-to-Date
Amarin stock rose from $2.35 at the close of market on December 29, 2017, to $18.97 at the close of market on November 21, 2018, reflecting a ~449% year-to-date rise. Amarin hit its 52-week high of $23.34 on November 6. Amarin’s net revenue in the first nine months of 2018 amounted to $151.9 million compared to $127.2 million in the same period of the previous year, reflecting a ~19% YoY (year-over-year) rise.
- ACCESSWIRE•16 days ago
Today's Research Reports on Trending Tickers: Agios Pharmaceuticals and Amarin Corporation
NEW YORK, NY / ACCESSWIRE / November 26, 2018 / U.S. equities lost footing on Friday amidst drop in oil prices and selloff in FAANG (Facebook, Amazon, Apple, Netflix and Google-parent Alphabet) stocks. ...
- GlobeNewswire•22 days ago
Amarin to Present at the Evercore ISI HealthCONx Conference
BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 20, 2018 -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of.
- ACCESSWIRE•23 days ago
Today's Research Reports on Trending Tickers: Amarin and Seattle Genetics
NEW YORK, NY / ACCESSWIRE / November 19, 2018 / U.S. equities finished mostly in the green on Friday as investors digested comments from President Donald Trump, expressing confidence in resolving the current ...
- Simply Wall St.•25 days ago
Amarin Corporation plc (NASDAQ:AMRN) Is Expected To Breakeven
Amarin Corporation plc’s (NASDAQ:AMRN): Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company’s Read More...
SmarterAnalyst•26 days agoH.C. Wainwright Sees over 80% Upside Potential for These Three Biotech Stocks
H.C. Wainwright analysts are convinced these three biotech stocks are worth a lot more than their current market values. All have recently been given price targets that suggest they could nearly double your money, or better. Here's why these analysts are willing to stick their necks out and predict huge gains ahead for Catalyst Pharmaceuticals (CPRX), Amarin Corporation (AMRN), and Ocular Therapeutix (OCUL). As the PDUFA goal date of November 28, 2018 for Firdapse in Lambert-Eaton Myasthenic Syndrome (LEMS) is approaching, H.C. Wainwright analyst Andrew Fein expects to see a straightforward nod from the FDA.
- Motley Fool•26 days ago
Why Amarin Corporation's Stock Is on the Mend Today
Amarin's business update at an investor conference helped to calm investors' nerves today.
- ACCESSWIRE•26 days ago
4 Stocks To Watch As Investors Dump Tech; Head To Healthcare
Investors are the least optimistic on tech stocks like these since the depths of the financial crisis and are instead directing attention to another corner of the market: healthcare. REDUCE-IT suggests that the residual 65-75% cardiovascular risk beyond cholesterol management can be significantly lowered with Vascepa in studied patients.
Market Realist•27 days agoHow Has Amarin Performed in 2018?
In the first nine months of 2018, Amarin reported revenues of $151.3 million, which is 20.0% YoY growth. Analysts expect Amarin to report a gross margin of 75.43% in 2018, which will be a rise of 25 basis points YoY. The company is expected to witness a gross margin of 76.67% in 2019, which will be an improvement by 123 basis points YoY.
- Motley Fool•27 days ago
Why Is Amarin Corporation Stock Up 300% in 2018?
Amarin's breakthrough in the cardiovascular care setting sent its shares soaring this year.
